Lisata Therapeutics (Lisata Therapeutics) EBIT per Share : $-3.13 (TTM As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Lisata Therapeutics EBIT per Share?

Lisata Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.80. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.13.

During the past 3 years, the average EBIT per Share Growth Rate was 44.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was 33.60% per year. During the past 10 years, the average EBIT per Share Growth Rate was 34.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Lisata Therapeutics's EBIT per Share or its related term are showing as below:

LSTA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 7.7 Med: 26.55 Max: 53.1
Current: 44.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Lisata Therapeutics was 53.10% per year. The lowest was 7.70% per year. And the median was 26.55% per year.

LSTA's 3-Year EBIT Growth Rate is ranked better than
90.96% of 1305 companies
in the Biotechnology industry
Industry Median: 3.5 vs LSTA: 44.50

Lisata Therapeutics's EBIT for the three months ended in Mar. 2024 was $-6.60 Mil.

Lisata Therapeutics EBIT per Share Historical Data

The historical data trend for Lisata Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics EBIT per Share Chart

Lisata Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-29.20

-18.61

-7.88

-11.12

-3.18

Lisata Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.86	-0.86	-0.73	-0.74	-0.80

Lisata Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Lisata Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-25.708	/	8.073
=	-3.18

Lisata Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-6.601	/	8.294
=	-0.80

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.13

Lisata Therapeutics (NAS:LSTA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Lisata Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Lisata Therapeutics (Lisata Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (NAS:LSTA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

0HS8:UK

Address

110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920

Website

https://www.lisata.com

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Executives

David W. Slack	director, officer: President & CBO	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Heidi Henson	director	2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Mohammad Azab	director	C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Erkki Ruoslahti	director	P.O. BOX 544, BUELLTON CA 93427
Steven S Myers	director	4695 MACAUTHUR COURT, EIGHTH FLOOR, NEWPORT BEACH CA 92660
Kristen K Buck	officer: EVP, R&D and CMO	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Todd C Girolamo	officer: CLO, SVP of Corp Dev	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Michael H. Davidson	director	OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Cynthia Schwalm	director	C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
David J Mazzo	director, officer: Chief Executive Officer	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Joseph Talamo	officer: SVP and CFO	CALADRIUS BIOSCIENCES, INC., 800 WESTCHESTER AVENUE. STE N341, RYE BROOK NY 10573
Douglas W Losordo	officer: See Remarks	13 FOX MEADOW RD, SCARSDALE NY 10583
Anford	10 percent owner	P.O. BOX 5039, SIOUX FALLS SD 57117
Health Sanford	10 percent owner	P.O. BOX 5039, SIOUX FALLS SD 57117